Your hard-earned money would be better spent elsewhere.

Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving -3.13% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.28%. On ...

These aren't for the faint of heart.

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (NASDAQ: RXRX) could be positioned to ride the ongoing wave of hype to ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...